Research progress on Kaposi sarcoma after solid organ transplantation
10.12464/j.issn.1674-7445.2024223
- VernacularTitle:实体器官移植术后卡波西肉瘤研究进展
- Author:
Yiling FANG
1
;
Yun MIAO
1
Author Information
1. Department of Organ Transplantation, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China.
- Publication Type:ReviewArticle
- Keywords:
Kaposi sarcoma;
Solid organ transplantation;
Human herpesvirus 8;
Kaposi sarcoma-associated herpesvirus;
Latency-associated nuclear antigen;
Mammalian target of rapamycin inhibitor;
Paclitaxel;
Doxorubicin
- From:
Organ Transplantation
2025;16(1):169-173
- CountryChina
- Language:Chinese
-
Abstract:
Kaposi sarcoma is an endothelial cell-derived malignant tumor caused by latent infection with human herpesvirus 8 (HHV-8) and reactivation under host immunosuppression. Solid organ transplant recipients are a high-risk group for Kaposi sarcoma. Compared with non-organ transplant recipients, post-transplant Kaposi sarcoma is often more aggressive and visceral involvement is more common. However, due to the relative rarity of Kaposi sarcoma after transplantation, routine pre-transplant serological screening for HHV-8 antibodies in donors and recipients and post-transplant prophylaxis for high-risk groups have not yet been carried out. And there is a lack of experience in the diagnosis and treatment of post-transplant Kaposi sarcoma. This article reviews the epidemiology, clinical manifestations, pathogenesis, diagnosis and treatment experience of Kaposi sarcoma in solid organ transplant recipients in recent years, aiming to attract the attention of transplant physicians and provide a reference for the diagnosis and treatment of this disease.
